← Back to Search

Heart Failure Patients with reduced or preserved Ejection Fraction for Genetic Polymorphism

N/A
Recruiting
Research Sponsored by October 6 University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown further reductions in heart failure hospitalization, cardiovascular events, and mortality, especially for heart failure patients. The SGLT2 gene, also known as SLC5A2 (solute carrier family 5 member 2), is located on chromosome 16 and is responsible for encoding SGLT2. Several SLC5A2 mutations alter SGLT2 expression, membrane location, or transporter function. Several common genetic variations were found in the SLC5A2 gene that may affect the response to treatment with SGLT2 inhibitors.

Eligible Conditions
  • Genetic Polymorphism
  • Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Median / Mean of Left Ventricular Ejection Fraction (LVEF) among studied genetic polymorphisms
Median / Mean of Left Ventricular End Diastolic Volumes among studied genetic polymorphisms
Median / Mean of Left Ventricular End Systolic Volumes among studied genetic polymorphisms
Secondary outcome measures
Median / Mean of quality of life measure {Kansas City Cardiomyopathy Questionnaire (KCCQ-12)} among studied genetic polymorphisms

Trial Design

1Treatment groups
Experimental Treatment
Group I: Heart Failure Patients with reduced or preserved Ejection FractionExperimental Treatment1 Intervention
Patients with reduced or preserved ejection fraction that have received the Guided Therapy (β-blockers, Diuretics, Angiotensin-converting enzyme (ACE) inhibitors or Angiotensin receptor blockers (ARBs) or Angiotensin Receptor-Neprilysin Inhibitor (ARNi) and Mineralocorticoid receptor antagonists (MRAs) then Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) (10 mg of dapagliflozin or empagliflozin) will be added at the study entry.

Find a Location

Who is running the clinical trial?

Beni-Suef UniversityOTHER
194 Previous Clinical Trials
49,515 Total Patients Enrolled
October 6 UniversityLead Sponsor
90 Previous Clinical Trials
6,010 Total Patients Enrolled
University of FloridaOTHER
1,342 Previous Clinical Trials
715,388 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Ahmed Essam 2023. "Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06201000.
~47 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top